An observational study in Colorectal Cancer and Brain Metastases, Adult, sponsored by Blokhin's Russian Cancer Research Center. Active, not recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Blokhin's Russian Cancer Research Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Colorectal Neoplasms with a site in Russia — 4 open to participants now, 13 under way, 2 of them phase 3. Colorectal Neoplasms · Russia.
Among the 22 studies in Colorectal Neoplasms with a site in Russia, this one is one of 2 that started in 2026, is one of 2 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 18th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 22 studies in Colorectal Neoplasms with a site in Russia are open now. Recruiting first, the newest first:
R-Pharm · Sites in Russia
Ages 18+
Saint Petersburg State University, Russia · Sites in Russia, China
Ages 18+
Guerbet · Sites in Russia, United States, Brazil and 5 more countries
Ages 18–64
Blokhin's Russian Cancer Research Center · Sites in Russia
Ages 18+
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 2014; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 700 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 244 across the 20 interventional studies, 365 across the 2 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 22 have an industry lead sponsor. The 10 most frequent:
Blokhin's Russian Cancer Research Center is the lead sponsor of 34 studies on the registry; 17 are open to participants now.
Blokhin's Russian Cancer Research Center has 6 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Colorectal Neoplasms with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457541Tomsk National Research Medical Center of the Russian Academy of SciencesMolecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI | 2026-12-31 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
| NCT05608044Agenus Inc.A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | 2027-09 |
| NCT07448662Blokhin's Russian Cancer Research CenterLocal Treatment Strategies for Brain Metastases of Colorectal Cancer | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 22 studies in Colorectal Neoplasms with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
COLBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of colorectal cancer.
Brain metastases (BM) from colorectal cancer (CRC) are a rare event, reported in less than 3% of patients with CRC. This course is associated with a dismal prognosis, and treatment of these patients remains challenging. The rarity of the event complicates research into both the effectiveness of local treatment methods and long-term oncological outcomes. Published studies are largely limited to single-center series with non-representative small patient cohorts, making it difficult to assess the reasons for such unsatisfactory treatment results.
Despite its rarity, there is growing evidence that the incidence of BM from CRC is increasing. Although direct epidemiological data are limited, many experts believe the detection rate has risen over the past quarter-century. This trend is likely multifactorial, attributed to advances in neuroimaging techniques and improved life expectancy due to the evolution of systemic therapy strategies.
However, this increase in detection has not translated into improved outcomes. Central nervous system (CNS) involvement in CRC remains associated with a dismal prognosis; median overall survival from the time of progression ranges from 2 to 5 months and has not substantially improved over recent decades. The aggressive disease course and the unmet clinical need for effective therapeutic strategies highlight the importance of large-scale, real-world data.
The primary objective of this study is to evaluate, in a large multi-institutional real-world cohort, the effectiveness of the following local treatment modalities for CRC BM:
Neurosurgical resection (NRS):
Radiotherapy (RT):
Combined local treatment modalities:
Investigators from a multi-institutional consortium of 15 major cancer centers across Russia and Belarus have initiated a collaborative effort to create, to the best of our knowledge, the largest and most comprehensive retrospective dataset of patients with CRC BM described to date. This dataset will pool clinical, pathological, and treatment-related data from patients diagnosed over the past quarter-century (2000-2025). Data to be collected for each patient will include:
Demographics and Baseline Characteristics
Primary Tumor Characteristics
Primary tumor sidedness:
Extracranial Disease Burden:
At initial cancer diagnosis:
At the time of BM diagnosis:
Intracranial Tumor Characteristics
Clinical Presentation
Timing of BM diagnosis:
Molecular Profile (where available)
Primary tumor:
- RAS status (mutant/wild-type/unknown; specify codon if available)
- BRAF status (mutant/wild-type/unknown; specify mutation if available)
Brain metastases:
- RAS status (mutant/wild-type/unknown; specify codon if available)
- BRAF status (mutant/wild-type/unknown; specify mutation if available)
Treatment-Related Data
◾ Lines of systemic therapy prior to BM diagnosis (number; categorized as 0, 1, 2, 3, 4, ≥ 5, unknown)
For radiotherapy:
Institutional and Period Data
Treatment period (by year of primary cancer diagnosis):
- 2000-2010
Primary Endpoints:
Time to Intracranial Progression (TTIP): Defined as the time from the date of initial colorectal cancer (CRC) diagnosis to the date of first BM detection. Based on this interval, patients will be categorized into two groups:
- Synchronous BM: BM diagnosed either prior to or within 2 months (≤ 60 days) of the primary tumor diagnosis.
- Metachronous BM: BM diagnosed more than 2 months (> 60 days) after the primary tumor diagnosis.
Central Nervous System Progression-Free Survival (CNS-PFS): Defined as the time from the date of first local treatment for BM to the date of subsequent intracranial progression or last instrumental follow-up (censored). Subsequent intracranial progression includes:
Secondary Endpoints:
Cumulative Incidence of Repeat Local Interventions: The cumulative proportion of patients undergoing any additional local treatment (neurosurgery or radiotherapy) for intracranial disease progression following initial local therapy. This endpoint captures the total burden of repeat procedures required for recurrent or new intracranial lesions during follow-up. Death without a repeat intervention is treated as a competing event in the analysis.
Statistical Analysis. All statistical analyses will be performed using IBM SPSS Statistics (version 29.0) and STATA (version 17.0, StataCorp LLC). A two-sided p-value \< 0.05 will be considered statistically significant.
- Descriptive Statistics. Categorical variables will be presented as absolute frequencies (n) and relative frequencies (%). Continuous variables will be assessed for normality. Normally distributed variables will be presented as mean with standard deviation (SD); non-normally distributed variables will be presented as median with interquartile range (IQR) or full range. The frequency of missing data will be reported for each variable. Where appropriate, multiple imputation using chained equations (MICE) will be considered to address missing data and minimize bias.
- Survival Analysis. Survival curves will be estimated using the Kaplan-Meier method. Median survival times with 95% confidence intervals (CI) will be reported. Comparison of survival curves between groups will be performed using the log-rank test and, where appropriate, the Breslow-Wilcoxon test.
For analyses of cause-specific death, competing risks methodology will be employed to estimate the cumulative incidence of death from intracranial progression, extracranial progression, and other causes, with death from competing causes treated as a competing event.
- Univariable and Multivariable Analysis. Univariable analysis will be performed to identify potential prognostic factors associated with survival outcomes. For categorical variables, the log-rank test will be used. For continuous variables, univariable Cox proportional hazards regression will be performed.
Variables with p \< 0.10 on univariable analysis, as well as clinically relevant factors regardless of significance, will be entered into multivariable Cox proportional hazards regression models to identify independent prognostic factors. The proportional hazards assumption will be tested. Results will be presented as hazard ratios (HR) with 95% CI.
- Preplanned subgroup analyses will be performed based on key variables such as local treatment modality, molecular profile, primary tumor sidedness, timing of brain metastases (synchronous vs. metachronous), and presence of extracranial disease.
Specific Analyses:
Handling of Missing Data. The proportion of missing data will be reported for all variables. Patterns of missingness will be explored. Where appropriate and assuming data are missing at random, multiple imputation using chained equations (MICE) will be performed to impute missing values for key variables in multivariable models.
The results of this large-scale, international study aim to provide high-level evidence to guide clinical decision-making and pave the way for personalized treatment approaches for this rare but challenging patient population.
The study population consists of adult patients (≥ 18 years) with histologically confirmed colorectal adenocarcinoma and radiologically ± histologically documented brain metastases.
Patients with synchronous or metachronous multiple primary tumors confined to the colon or rectum are eligible. Patients referred after initial local treatment for brain metastases are included provided that complete documentation of the first treatment modality is available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Radiologically ± histologically confirmed , including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (≥ 18 years) with histologically confirmed colorectal adenocarcinoma and radiologically ± histologically documented brain metastases
Procedure: Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR) · Radiation: Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT) · Other: Combined Local Treatment Modalities · Other: No Local Treatment
Patients in this cohort underwent neurosurgical resection as the primary local treatment for brain metastases. Surgical approaches include: * En-bloc resection (EBR): gross-total removal of the tumor as a single, intact specimen with no residual disease on postoperative MRI; * Total piecemeal resection (TPR): gross-total removal of the tumor in multiple fragments with no residual disease on postoperative MRI * Subtotal (SPR) or partial (PPR) piecemeal resection: incomplete removal of the tumor, with macroscopic residual disease on postoperative MRI. This includes: * Subtotal resection: 75-90% of tumor volume removed * Partial resection: 30-75% of tumor volume removed * Extent of resection unknown: surgical resection performed, but the precise extent could not be determined from available records
Patients in this cohort received radiotherapy as the primary local treatment modality for brain metastases. Treatment modalities include: * Stereotactic radiosurgery (SRS): single-fraction, high-precision radiation with a prescribed dose \> 12 Gy; * Staged stereotactic radiosurgery (stSRS): radiosurgery delivered in 2-3 stages, typically 2-4 weeks apart, allowing for tumor volume reduction between stages; * Stereotactic radiotherapy (hypofractionated) (SRT): stereotactic radiation delivered in multiple fractions, including: * 3 fractions (single dose 7-9 Gy, total dose 21-27 Gy); * 5 fractions (single dose 6-7 Gy, total dose 30-35 Gy); * 7 fractions (single dose 5 Gy, total dose 35 Gy). * Whole-brain radiotherapy (WBRT): conventional fractionated radiation to the entire brain.
Patients in this cohort received a combination of local treatment approaches. This includes: * NRS with postoperative WBRT; * NRS with postoperative SRT/SRS; * Preoperative SRS followed by NRS; * Combination radiotherapy (SRS and WBRT, SRT and WBRT, SRS and SRT)
Patients in this cohort did not receive any local treatment for their brain metastases. This may include patients receiving best supportive care (BSC) (typically includes the administration of corticosteroids for symptomatic control of peritumoral edema and neurological symptoms) or systemic therapy alone. Reasons for not receiving local treatment may include poor performance status, extensive intracranial disease, or patient preference.
Overall Survival (OS)
Time from the date of brain metastasis diagnosis to the date of death from any cause or last follow-up (censored)
Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years (censored)
Time to Intracranial Progression (TTIP)
Time from the date of initial colorectal cancer diagnosis to the date of first brain metastasis detection. Based on this interval, patients will be categorized as synchronous (≤ 60 days from primary diagnosis) or metachronous (\> 60 days).
Time frame: From date of initial cancer diagnosis until first brain metastasis detection, assessed up to 10 years
Central Nervous System Progression-Free Survival (CNS-PFS)
Time from the date of first local treatment for brain metastases to the date of subsequent intracranial progression or last instrumental follow-up (censored). Intracranial progression includes: continued growth of treated lesion (≤ 6 months after treatment), local recurrence of treated lesion (\> 6 months after treatment), or development of new intracranial lesions.
Time frame: From the date of first local treatment for BM until subsequent intracranial progression or last imaging follow-up, assessed up to 5 years (censored)
Overall Survival from Initial Diagnosis
Time from the date of initial colorectal cancer diagnosis to the date of death from any cause or last follow-up.
Time frame: From date of initial cancer diagnosis until death or last contact, assessed up to 5 years
Cancer-Specific Survival
Time from brain metastasis diagnosis to death from cancer progression (intracranial and/or extracranial), with death from other causes treated as a competing event
Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years
Cumulative Incidence of Death from Intracranial Progression
Death directly attributable to neurological complications resulting from progressive intracranial disease, analyzed using competing risks methodology with death from other causes as competing events.
Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years
Cumulative Incidence of Death from Extracranial Progression
Death attributable to systemic disease progression in the presence of controlled intracranial disease, analyzed using competing risks methodology with death from other causes as competing events.
Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years
Cumulative Incidence of Death from Non-cancer Causes
Death from causes unrelated to cancer progression, analyzed using competing risks methodology with cancer-related deaths as competing events.
Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years
Cumulative Incidence of Repeat Local Interventions
The cumulative proportion of patients undergoing any additional local treatment (neurosurgery or radiotherapy) for intracranial disease progression following initial local therapy. This endpoint captures the total burden of repeat procedures required for recurrent or new intracranial lesions during follow-up. Death without a repeat intervention is treated as a competing event in the analysis
Time frame: From date of first local treatment until the date of second local intervention or last follow-up, assessed up to 5 years (censored)
Plan to share: Yes — De-identified individual participant data collected for this study, including data dictionaries, will be available upon reasonable request from the corresponding author beginning 6 months after publication and ending 5 years following article publication. Data will be shared with researchers who provide a methodologically sound proposal for use approved by an independent review committee. Proposals should be directed to the corresponding author.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Individual participant data and supporting information will become available 6 months after publication of the primary results and will remain available for 5 years following article publication.
Access criteria: Access will be granted to qualified academic researchers who submit a methodologically sound research proposal for use approved by an independent review committee.
Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blokhin's Russian Cancer Research Center